ANORO ELLIPTA is a prescription medicine
An inhalation powder drug product for delivery of a combination of the anticholinergic umeclidinium and vilanterol a LABA to patients by oral inhalation.
The inhaler contains 2 double-foil blister strips with micronized umeclidinium bromide 74.2 mcg, and micronized vilanterol trifenatate 40 mcg.
ANORO™ ELLIPTA™ (umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder)
Used to treat chronic obstructive pulmonary disease (COPD) in adults.
Used long term as 1 inhalation, 1 time each day, to improve symptoms of COPD.
Not used to treat sudden symptoms of COPD.
Does not replace a rescue inhaler.
Not for the treatment of asthma.
Can cause serious side effects, including: sudden breathing problems, and serious allergic reactions.
After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream.
The ANORO ELLIPTA delivers 55 mcg of umeclidinium and 22 mcg of vilanterol per dose when tested at a flow rate of 60 L/min for 4 seconds.
The amount of drug delivered to the lung depends on patient factors, such as inspiratory flow profile.
Used long term as 1 inhalation, 1 time each day, to improve symptoms of COPD.
Not used to treat sudden symptoms of COPD.
Does not replace a rescue inhaler.
Side effects, include: sudden breathing problems, rash, hives, swelling of the face, mouth, and tongue, hypertension, tachycardia, arrhythmias, chest pain, tremor, nervousness, eye problems, including acute narrow-angle glaucoma, nausea or vomiting, blurred vision, seeing halos, seeing bright colors around lights, red eyes, urinary retention, hyperglycemia, hypokalemia, sore throat, constipation, diarrhea, and muscle spasms,